Q.5 Hypersensitivity involved in blood transfusion and erythroblastosis fetalis is

1. Type I hypersensitivity

2. Type II hypersensitivity

3. Type III hypersensitivity

4. Type IV hypersensitivity

Here’s a comprehensive, SEO-friendly article on the topic, optimized for search engines with the keyphrase “hypersensitivity in blood transfusion and erythroblastosis fetalis.” I’ve structured it for readability, included the correct answer upfront, and explained all options with clear immunology basics tailored to biology students.

Hypersensitivity in Blood Transfusion and Erythroblastosis Fetalis: Type II Explained

Blood transfusions and erythroblastosis fetalis (also called hemolytic disease of the newborn) can trigger dangerous immune reactions. The correct answer to the question—”Hypersensitivity involved in blood transfusion and erythroblastosis fetalis is”—is Type II hypersensitivity. This antibody-mediated response destroys cells via IgG or IgM antibodies targeting specific antigens on cell surfaces.

Let’s break it down: first, the mechanism in these conditions, then explanations of all four options with real-world examples.

Why Type II Hypersensitivity Fits Blood Transfusions and Erythroblastosis Fetalis

Type II (cytotoxic) hypersensitivity occurs when antibodies bind to antigens on cells or tissues, leading to cell destruction through complement activation, phagocytosis, or antibody-dependent cellular cytotoxicity (ADCC).

• In blood transfusions: Mismatched ABO or Rh blood groups cause recipient antibodies to attack donor red blood cells (RBCs). IgM anti-A/B antibodies trigger rapid hemolysis, causing acute hemolytic transfusion reactions—fever, chills, back pain, and shock.

• In erythroblastosis fetalis: Rh-negative mothers develop IgG anti-Rh antibodies after exposure to Rh-positive fetal blood (e.g., during pregnancy or birth). These cross the placenta in subsequent pregnancies, destroying the Rh-positive fetus’s RBCs. This leads to severe anemia, jaundice, and hydrops fetalis.

Think of it like a misguided security team: antibodies tag “foreign” cells for destruction, but here they target innocent RBCs. Prevention includes cross-matching for transfusions and RhoGAM for Rh-incompatible pregnancies.

Explanation of All Hypersensitivity Types

Gell and Coombs classified hypersensitivities into four types based on immune mechanisms. Here’s how each works, with why it doesn’t (or does) apply:

Type I Hypersensitivity: Immediate IgE-Mediated

Involves IgE antibodies binding mast cells and basophils, releasing histamine upon allergen exposure. Causes rapid symptoms like hives, anaphylaxis, or asthma (e.g., peanut allergy).

• Why not here? No cell destruction; it’s soluble mediators, not cytotoxic. Blood reactions aren’t “immediate” like hay fever.

Type II Hypersensitivity: Antibody-Mediated Cytotoxic (Correct)

As detailed above—targets fixed cell antigens (e.g., RBCs in transfusions or Goodpasture’s syndrome). Complement or phagocytes lyse cells.

• Key fit: Direct antibody attack on blood cells matches both conditions perfectly.

Type III Hypersensitivity: Immune Complex-Mediated

Soluble antigen-antibody complexes deposit in tissues, activating complement and neutrophils. Leads to inflammation (e.g., serum sickness, SLE, or Arthus reaction).

• Why not here? Involves circulating complexes, not cell-bound antigens. Transfusion reactions are purely cytotoxic, without widespread deposits.

Type IV Hypersensitivity: Delayed T-Cell Mediated

T-cells (not antibodies) drive inflammation 48-72 hours later (e.g., contact dermatitis from poison ivy or tuberculin test).

• Why not here? No T-cell involvement; reactions are antibody-driven and fast (minutes to hours).

Key Takeaways for Students and Clinicians

Type II hypersensitivity dominates transfusion medicine and neonatal care because blood group antigens sit right on RBC surfaces—perfect targets for cytotoxic antibodies. Master this for exams in immunology, hematology, or OB-GYN.

Correct Answer: 2. Type II hypersensitivity